For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1092/Stem-Cell-Technologies-World-Market-Outlook-2013-2023

1. Stem Cell Technologies:
World Market Outlook 2013-2023
©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

2. Contents
1. Executive Summary
1.1 Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods
2. Overview of the Stem Cells Market, 2013-2023
2.1 Strong Market Performance Expected 2013-2023
2.2 Cancer Segment Represents Bulk of Stem Cell Therapy Revenues, 2013
2.2.1 Other Therapeutic Areas to Gain Ground by 2023
2.2.2 Market Breakdown Focuses on Key Therapeutic Areas
2.3 Which Types of Stem Cells Matter for the Market?
2.3.1 The Discovery of Stem Cells
2.3.2 Embryonic Stem Cells (ESCs) Enter the Picture
2.3.3 Only ESCs and Induced Pluripotent Adult Cells (IPSCs) Have Pluripotency
2.3.4 MSCs Prominent in Clinical Trials
2.3.5 Autologous and Allogeneic Properties
2.3.6 Different Cell Advantages and Disadvantages
2.4 The Global Regulatory Environment for Stem Cells
2.4.1 US: No Morality Clause, Much Venture Capital
2.4.1.1 ESC Controversy Now Settled?
2.4.1.2 FDA Vs Regenerative Sciences
2.4.2 Japan: Liberal on hESCs
2.4.2.1 First-in-Human iPSC Trial Announced in 2013
2.4.3 Europe: No Consistent Position Across the Continent
2.4.3.1 The Brüstle Ruling: Dead and Buried?
2.4.3.2 The UK Leads in European Stem Cells R&D
2.4.4 Rest of the World
www.visiongain.com

3. Contents
2.4.4.1 South Korea: Leading the Way in MSC Approvals
2.4.4.2 China: Liberal Laws on Stem Cell Research
2.4.4.3 Israel – Long-Term Research Activity
2.4.4.4 ‘Stem Cell Tourism’
2.8.1 The Vaccines Market
3. Stem Cell Cancer Therapeutics Segment 2013-2023
3.1 HSCT Will Underpin the Growth of the Cancer Segment in the 2013-2023 Period
3.2 Stem Cells: 45 Years as a Major Part of Blood Cancer Treatment
3.2.1 Autologous HSCT Operations Still Dominate Segment
3.2.2 Allogeneic HSCT: More Rejections, Fewer Relapses
3.2.3 GvHD: The Major Issue for HSCT
3.2.4 Peripheral Blood: More Anti-Tumour Effect, More GvHD Risk
3.2.5 The Rise of Umbilical Cord Blood
3.2.6 Around 60,000 HSCT Operations Performed Worldwide in 2012
3.2.7 HSCT Costly, Medicare Coverage Selective
3.2.8 Haematological Malignancies the Major Indication for HSCT
3.2.9 HSCT Addresses Cancers Representing a $20bn+ Market
3.2.10 From Successful Procedure to Successful Products? The Next Stage for the HSCT Sector
3.3 Pipeline Maturing, with First Approval in 2012
3.3.1 Osiris Therapeutics – Prochymal Finally Makes it to Market
3.3.1.1 Osiris Leads the Pack in Stem Cell Therapeutics
3.3.1.2 Using MSCs for Immunosuppression
3.3.1.3 Positive Results in Acute Paediatric GvHD
3.3.1.4 An Important Role to Play in the Future of HSCT
3.3.2 The Clinical-Stage Pipeline: Two More Candidates in Phase 3
3.3.3 Gamida Cell – StemEx: The Next Stem Cell Product to Market?
3.3.3.1 Survival at 100 Days Improved by StemEx in Latest Trial
3.3.3.2 FDA Remains Unconvinced
3.3.3.3 NiCord Heads Up a Pipeline of New Cell Therapy Products
www.visiongain.com

4. Contents
3.3.3.4 NiCord Promising So Far
3.3.4 Mesoblast – Using Mesenchymal Precursors to Enrich Cord Blood
3.3.4.1 Phase 3 Trial Measuring 100-Day Survival Rates and Engraftment Efficiency
3.3.4.2 A Competitor for Gamida Cell?
3.3.5 Novartis Pharmaceuticals – Cord Blood Transplant Candidate
3.3.5.1 Swiss Giant with Multiple Stem Cell Interests
3.3.6 Medipost – Promostem Uses Cord Blood MSCs to Prevent GvHD
3.3.7 CytoMedix – Improving Engraftment
3.3.8 Lentigen – LG631-CD34 for Chemoprotection
3.3.9 Athersys – MultiStem Trialled in Blood Cancers
3.3.10 HomeoTherapy – MSCs for GvHD
3.3.11 Pluristem Soon to Join the Hunt?
3.3.12 Other Stem Cell Oncology Prospects
3.3.13 Ancillary Products for the HSCT Setting
3.3.14 Targeting Cancer Stem Cells (CSCs)
3.3.15 Immunovative Therapies – Building on HSCT for a Cellular Anticancer Therapy
3.4 How Much Growth Potential Do Stem Cells Have in Cancer Indications?
4. Stem Cell Cardiovascular Therapeutics Segment, 2013-2023
4.1 Segment Set for 40%+ CAGR in 2013-2023 Period
4.2 Can Stem Cells Heal the Heart and Vasculature?
4.2.1 AMI, CLI and Stroke Major Ischaemic Disease Targets
4.2.2 Cerebrovascular Treatments for Stroke
4.2.3 What is the Heart’s Own Stem Cell?
4.2.4 MSCs Support Cardiac Stromal Lineages
4.2.5 The Mysterious Efficacy of Adult Stem Cells in the Heart
4.2.6 Cells Have Therapeutic Effects Despite Rapid Clearance
4.2.7 A New Generation of Cardiovascular Stem Cells May Need to Look Beyond MSCs
4.2.8 Are MSCs Safe and Efficacious?
www.visiongain.com

5. Contents
4.2.9 Cardiovascular and Cerebrovascular Conditions Are World’s Most Fatal Diseases
4.2.10 Cardiovascular Drugs Market Exceeded $110bn in 2012
4.3 Cardiovascular Stem Cell Pipeline and Products, 2013-2023
4.3.1 FCB-Pharmicell – Hearticellgram-AMI, the First Approved Cardiovascular Stem Cell
Treatment
4.3.1.1 Performance So Far
4.3.1.2 Will Hearticellgram Impress Regulators Outside Korea?
4.3.2 The Largest Pipeline in the Stem Cells Market
4.3.3 Baxter: Big Pharma Leader in Cardiovascular Stem Cells
4.3.3.1 Exercise Tolerance and Angina Frequency Reduced
4.3.3.2 Wider Potential for this Treatment
4.3.4 Cardio3 Bioscience – Cardiopoiesis Platform for Heart Regeneration
4.3.4.1 Positive Phase 2 Data
4.3.4.2 Phase 3 Trial Begins Amid Controversy
4.3.5 Bioheart – MyoCell in new MIRROR Trial
4.3.5.1 Muscle Cells the Basis of MyoCell
4.3.5.2 Seeking Expanded Access for Compassionate Use
4.3.6 NeoStem – Diversified Outfit with One of the Leading Candidates
4.3.6.1 AMR-001 to Treat Acute Myocardial Infarction
4.3.6.2 NeoStem Head-to-Head with Baxter in the HSC Cardiovascular Treatment Space
4.3.7 Aastrom Biosciences: Ixmyelocel-T for Cardiovascular Disease
4.3.7.1 A Complex Multicellular Mixture
4.3.7.2 Company Now Focusing on DCM
4.3.8 Athersys – MultiStem is a Potential Cardiovascular Treatment
4.3.8.1 Addressing Ischaemic Stroke
4.3.9 CytoMedix – Three Clinical Candidates in the Cardiovascular Segment
4.3.9.1 ALD-401 – Repairing Stroke Damage?
4.3.9.2 ALD-301 – Entering Phase 2 in PAD Patients
4.3.9.3 ALD-201 – Signs of Efficacy in Phase 1 Heart Failure Trial
4.3.10 TCA Cellular Therapy – Mesendo Autologous Treatments
www.visiongain.com

6. Contents
4.3.10.1 Preparing for Phase 3 with CLI Treatment
4.3.11 Medistem – The ‘Universal Donor’ Cell
4.3.11.1 Trial in CLI the First Clinical Test for ERC
4.3.11.2 Scalability a Major Advantage for Medistem
4.3.12 Stemedica Cell Technologies – Ischaemic Tolerant Stem Cell Platform
4.3.12.1 Two Trials in Progress for Allogeneic MSCs
4.3.13 Mesoblast – Cell Therapy for Myocardial Infarction
4.3.13.1 Teva Collaborating on Cardiovascular Stem Cell Therapy R&D
4.3.14 Pluristem – Cell Therapy for Myocardial Infarction
4.3.14.1 Progress in PAD and CLI
4.3.15 Osiris – Prochymal Cell Therapy for Myocardial Infarction
4.3.16 Cytori Therapeutics – Adipose-Derived Cells for Acute Myocardial Infarction
4.3.17 Stempeutics – Emerging Bangalore Company Targets CLI
4.3.18 BioCardia – Comparing Autologous and Allogeneic MSCT Options
4.3.19 Apceth – Mesenchymal Stem Cells for Advanced Peripheral Arterial Occlusive Disease
4.3.20 Arteriocyte – Nanex Technology to Treat CLI
4.3.21 Capricor – Using Cardiosphere-Derived Cells for Heart Repair
4.3.21.1 Phase 1/2 Trial Now Underway
4.3.22 Garnet BioTherapeutics – GBT009 for Cardiac Tissue Preservation
4.3.23 Biogenea-Cellgenea – Cardiogenea to Enter the Clinical Pipeline
4.3.24 Other Stem Cell Cardiovascular Prospects
4.4 Can Stem Cells Be a Game-Changer in the Cardiovascular Sphere?
5. Stem Cell CNS Therapeutics Segment, 2013-2023
5.1 The Biggest Stem Cell Therapeutic Revolution of All will Begin to Take Shape by 2023
5.2 Stem Cells the Best Hope for Many Serious CNS Conditions
5.2.1 Segment Awaits First Breakthrough Approval
5.2.2 Human NSCs Successfully Isolated
5.2.3 NSCs Reach the Clinic
www.visiongain.com

7. Contents
5.2.4 CNS Segment the Major Focus for ESC Research
5.2.5 MSCs: Can Glial Cell and Astrocyte Formation Help Neurological Conditions?
5.2.6 Could ‘Resetting’ the Immune System Treat MS?
5.2.7 ALS: Rare Disease Could be the First Neurodegenerative Condition to Fall to Stem Cell
Treatment
5.2.8 PD: Positive Signs from Early Experiments in Cellular Treatment
5.2.9 Dry AMD: A Major Global Unmet Need
5.2.10 Several Multi-Billion Dollar Potential Markets in the Sights of CNS Stem Cell Developers
5.3 Which Product Will Be First to Phase 3 Trials in the CNS?
5.3.1 BrainStorm Cell Therapeutics – NurOwn Cells for Spinal Cord Injury and ALS
5.3.1.1 Validating the NurOwn Approach
5.3.1.2 ALS Trial Ongoing
5.3.2 Neuralstem – Neural Stem Cells for Synaptic Repair and Neuroprotection
5.3.2.1 Phase 2 Trial in ALS Enrolling by Invitation
5.3.2.2 Chronic Spinal Cord Injury Treatment to Follow
5.3.3 Mesoblast – A New Option in Neovascular AMD?
5.3.3.1 CNS Stem Cells from Dental Pulp
5.3.4 Advanced Cell Technology – Leading the Field in ESC Clinical Trials
5.3.4.1 Continued Progress in Stargardt’s Macular Dystrophy in 2013
5.3.4.2 Early Signals of Efficacy?
5.3.5 StemCells – The Leading Player in the NSC Space?
5.3.5.1 HuCNS-SC Product Proving Itself in Rare Indications
5.3.5.2 Moving on to Spinal Cord Injury and AMD
5.3.5.3 Alzheimer’s Disease and Stroke to Follow?
5.3.6 TCA Cellular Therapy – Mesendo for ALS
5.3.7 Corestem – Autologous Bone Marrow Stem Cells for ALS
5.3.8 ReNeuron – ReN001 is a Potential New Stroke Treatment
5.3.8.1 Foetally-Sourced Cells Have Wide Potential Application
5.3.9 SanBio – SB623 for Ischaemic Stroke
5.3.9.1 Future SanBio Programmes at Preclinical Stage in 2013
www.visiongain.com

8. Contents
5.3.10 Pfizer – Collaborating on the London Project to Cure Blindness
5.3.11 Stemedica Cell Technologies- Ischaemic RPE Cells
5.3.11.1 NSC Lines from Donated Brain Tissue
5.3.12 NeuroGeneration – Investigating Human NSCs
5.3.13 Companies at Preclinical Stage
5.3.13.1 RhinoCyte – Stem Cells from the Nasal Passage to the Spinal Cord
5.3.13.2 Theradigm - Neural Cells for CNS Disorders
5.3.13.3 Biotime – Targeting AMD with ESCs
5.3.14 Other Companies with Technologies of Interest
5.3.14.1 iPierian – Bringing iPSCs to the CNS Market?
5.4 Will CNS Stem Cells Fulfil Their Perceived Therapeutic Potential?
6. Stem Cell Therapeutics in Other Disease Areas, 2013-2023
6.1 A Diverse Range of Approvals will Drive Segment Growth to 2023
6.2 Other Indications for Stem Cell Treatment
6.2.1 Curing Orphan Diseases with HSCT
6.2.2 Genetically-Modified HSCs May Cure HIV, Among Other Diseases
6.2.3 Stem Cells for Osteogenesis
6.2.4 Several Stem Cell Osteobiologics Already Marketed
6.2.5 Perianal Fistula Treatment Indicates Stem Cells’ Potential in Tissue Repair
6.2.6 A New Option for Many Autoimmune Disorders
6.2.7 Can Stem Cells Cure Diabetes?
6.2.8 Mending the Liver
6.2.9 Long-Range Possibilities
6.3 Which Other Indications Will See the First Approvals?
6.3.1 Medipost - Cartistem, ‘World’s First Allogeneic Stem Cell Drug’
6.3.2 Anterogen – Cupistem, Adipose-Derived Stem Cells for Anal Fistula
6.3.3 R&D Ranges Broadly Across Disease Areas
6.3.4 TiGenix – Phase 3 Data for Cx601 Expected In July 2014
www.visiongain.com

9. Contents
6.3.4.1 ‘First Ever Signal of Clinical Activity of a Cell Therapy in RA’
6.3.4.2 ChondroCelect Already on the Market
6.3.5 Osiris Take on Crohn's Disease - Another Possible Use for Prochymal
6.3.5.1 Chondrogen: New Osteoarthritis Candidate
6.3.6 Mesoblast – Treating Back Pain and Disc Degeneration
6.3.6.1 IV Precursor Cells Seeking Out New Indications
6.3.7 Athersys – Pfizer Collaboration in Ulcerative Colitis
6.3.8 Celgene Cellular Therapeutics – Targeting Multiple Inflammatory Conditions
6.3.9 AlloCure – AC607 for Anti-Inflammatory Effects
6.3.10 Gamida Cell – Potential Sickle Cell Anaemia Treatment Option
6.3.11 GlaxoSmithKline – GSK2696273 Stem Cell Gene Therapy
6.3.12 Alliancells Bioscience Corporation – Possible RA Treatment
6.3.13 ViroMed – Stem Cell Gene Therapy for Chronic Granulomatous Disease
6.3.14 S-Evans Biosciences – Menstrual Stem Cells for Hepatic Disease
6.3.15 Cytomedix – ALD-601 for Lysosomal Storage Diseases
6.3.16 Cellonis Biotechnology – Commercialising Research on Stem Cells in Diabetes
6.3.17 Other Companies in the Hunt for New Stem Cell Applications
6.4 Can We Expect A Clinical Breakthrough for Stem Cells in Other Therapeutic Areas by 2023?
7. Non-Therapeutic Applications of Stem Cell Technologies Segment,
2013-2023
7.1 Cell-Based Assays will Help Expand this Segment in 2013-2023 Period
7.2 A Diverse Range of Business Models Emerging
7.2.1 Stem Cell Banking: Growing Demand Worldwide
7.2.2 Stem Cell Supply and Processing: iPSCs the New Driver?
7.2.3 Stem Cell-Based Assays: Major Potential for Preclinical Screens
7.2.4 Research, Reagents, and Other Non-Therapeutic Stem Cell Revenue Streams
7.3 What Will the Main Growth Areas be for Non-Therapeutic Stem Cell Activities?
www.visiongain.com

10. Contents
8. Qualitative Industry Analysis, 2013
8.1 Strengths: Stem Cells Are Finally Proving Their Worth
8.2 Weaknesses: Many Difficulties Still to Overcome
8.3 Opportunities: Stem Cells Have Unprecedented Clinical Potential
8.4 Threats: Regulatory and Commercial Instability Threatens the Field
8.5 Social Concerns: A Controversial Technology
8.6 Technological Developments: Stem Cell Science Still on the March
8.7 Economic Factors: Funding Gaps a Concern
8.8 Political Issues: State Attitudes Key to Research Environment
9. Research Interviews
9.1 Interview with Dr Antonio Lee, Associate Director Business Development, Medipost
9.1.1 Overview of Cartistem
9.1.2 Global Regulatory Variation in Cellular Cartilage Repair Field
9.1.3 Precedents and Competition for Cartistem
9.1.4 Cord Blood-Derived MSCs: Advantages and Challenges
9.1.5 Medipost’s Pipeline
9.2 Interview with Dr Alan Trounson, President, California Institute for Regenerative Medicine
(CIRM)
9.2.1 Improved Funding in the Stem Cells Field
9.2.2 MSCs: Major Potential or Merely a Placeholder?
9.2.3 CIRM Investment Strategies
9.2.4 The Changing Regulatory Environment Worldwide
9.2.5 Key Trends for the Next Five to Ten Years
9.3 Interview with Dr Andras Nagy, Senior Scientist, Samuel Lunenfeld Research Institute,
Mount Sinai Hospital
9.3.1 Overview of the Current State of the iPSC Field
9.3.2 Genomic Stability and Other Potential Issues for iPSCs
www.visiongain.com

11. Contents
9.3.3 Potential for Treating and Modelling Diseases with iPSCs
9.3.4 Reprogramming Without Transgenes
9.3.5 Possibilities for Directly-Converted Cells
10. Conclusions
10.1 Stem Cell Technologies Will Begin to Break Through by 2017
10.2 Market to Record Double-Digit CAGR to 2023
10.3 Oncology and Non-Therapeutic Uses to Dominate To 2017
10.4 CNS and Cardiovascular Treatments to Gain Market Share by 2023
10.5 Strong R&D Pipeline to Drive Market Growth
10.6 Radical Clinical and Commercial Possibilities for Stem Cells in the Longer Term
10.7 Challenges for the Stem Cells Market
10.8 Concluding Remarks
www.visiongain.com

12. Contents
List of Tables
Table 2.1 Stem Cells Market: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 2.2 Stem Cells Market: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 2.3 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2012
Table 2.4 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares
(%), 2012-2017
Table 2.5 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2017
Table 2.6 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares
(%), 2018-2023
Table 2.7 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2023
Table 2.8 Potency and Source of Stem Cells
Table 2.9 Germ Layers and Their Associated Types of Cells and Organs
Table 2.10 Main Types of Stem Cells and Their Properties, 2013
Table 2.11 Sources of Stem Cells for Medical Applications, 2013
Table 3.1 Cancer Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.2 Cancer Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.3 Comparative Characteristics of Bone Marrow, Peripheral Blood and Cord Blood for
HSCT, 2013
Table 3.4 Indications with Medicare Coverage for HSCT, 2013
Table 3.5 Malignancies and Other Haematological Diseases Treated with HSCT, 2013
Table 3.6 Selected Companies Developing Stem Cell Cancer Treatments, 2013
Table 4.1 Cardiovascular Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.2 Cardiovascular Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 4.3 Selected Companies Developing Stem Cell Cardiovascular Treatments, 2013
Table 5.1 CNS Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 5.2 CNS Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 5.3 Selected Companies Developing Stem Cell Cancer Treatments, 2013
Table 6.1 Other Therapeutic Areas Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 6.2 Other Therapeutic Areas Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
www.visiongain.com

13. Contents
Table 6.3 Diseases Other than Cancers to be Treated with HSCT, 2013
Table 6.4 Processes Involved in Bone Healing
Table 6.5 Selected Companies Developing Stem Cell Cancer Treatments, 2013
Table 7.1 Non-Therapeutic Applications Segment: Revenues ($m), AGR (%), CAGR (%), 20122017
Table 7.2 Non-Therapeutic Applications Segment: Revenues ($m), AGR (%), CAGR (%), 20182023
Table 7.3 Non-Therapeutic Applications of Stem Cells: Estimated Breakdown of Activities,
Revenues ($m), Segment Share (%), 2012
Table 7.4 Selected US Stem Cell Banking Companies, 2013
Table 7.5 Selected Non-US Stem Cell Banking Companies, 2013
Table 7.6 Selected Stem Cell Supply and Processing Companies, 2013
Table 7.7 Selected Companies with Involvement in Stem Cell-Based Assays, 2013
Table 7.8 Selected Companies with Other Stem Cell-Related Activities, 2013
Table 8.1 World Stem Cells Market: Strengths and Weaknesses, 2013
Table 8.2 World Stem Cells Market: Opportunities and Threats, 2013
Table 8.3 World Stem Cells Market: STEP Analysis, 2013-2023
Table 10.1 Stem Cell Products: Approved and in Late-Stage Trials, 2013
www.visiongain.com

14. Contents
List of Figures
Figure 2.1 World Biological Drugs Market: Total Revenues ($m),
Figure 2.1 Stem Cells Market: Revenues ($m), 2012-2023
Figure 2.2 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2012
Figure 2.3 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2017
Figure 2.4 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2023
Figure 2.5 Stem Cells Market Breakdown by Segment: Revenues ($m), 2012-2023
Figure 2.6 Stem Cells Market Breakdown by Segment: Revenues ($m), 2012, 2017, 2023
Figure 2.7 The Early History of Stem Cell Discovery and Development
Figure 3.1 Cancer Segment: Revenues ($m), 2012-2023
Figure 3.2 Drivers and Restraints for Stem Cell Cancer Therapies, 2013
Figure 4.1 Cardiovascular Segment: Revenues ($m), 2012-2023
Figure 4.2 Drivers and Restraints for Stem Cell Cardiovascular Therapies, 2013
Figure 5.1 CNS Segment: Revenues ($m), 2012-2023
Figure 5.2 Drivers and Restraints for CNS Stem Cell Therapeutics, 2013
Figure 6.1 Other Therapeutic Areas Segment: Revenues ($m), 2012-2023
Figure 6.2 Drivers and Restraints for Stem Cell Therapeutics in Other Therapeutic Areas, 2013
Figure 7.1 Non-Therapeutic Applications Segment: Revenues ($m), 2012-2023
Figure 7.2 Non-Therapeutic Applications of Stem Cells: Estimated Breakdown of Activities,
Revenues ($m), Segment Share (%), 2012
Figure 7.3 Drivers and Restraints for Non-Therapeutic Applications of Stem Cells, 2013
Figure 10.1 Stem Cell Technologies Market Revenues ($m), 2012-2017
Figure 10.2 Stem Cell Technologies Market Revenues ($m), 2018-2023
Figure 10.3 Stem Cell Market Segments: Revenues ($m), 2012-2017
Figure 10.4 Stem Cell Market Segments: Revenues ($m), 2018-2023
www.visiongain.com

15. Contents
Organisations Mentioned in the Report
Abbott Laboratories
3DM
Aastrom Biosciences
Adistem
Advanced Cell Technology
Alder Biopharmaceuticals
AllCells
Alliancells Bioscience Corporation
AlloCure
Amgen
Amorcyte
Angel Biotechnology
Angiostem
Angiotech
Anterogen
Antria
apceth
Aristotle University of Thessaloniki
Arteriocyte
Athersys
Auriga Ventures
Axiogenesis
Baxter Healthcare
Beth Israel Deaconess Medical Center
BioCardia
BioE
Biogenea-Cellgenea
Bioheart
Bio-Matrix
www.visiongain.com

16. Contents
BioMet Orthopedics
Biotime
Bluebird Bio
BrainStorm Cell Therapeutics
Bresagen
California Institute for Regenerative Medicine (CIRM)
California Stem Cells
Capricor
Cardio3 Bioscience
Cardiogenesis
Cedars-Sinai Heart Institute
Celgene Cellular Therapeutics
Cell Cure Neurosciences
CellCentric
Cellectis
Cellerant Therapeutics
Cellonis Biotechnology
CellSeed
Cellular Dynamics International
Cephalon
Cha General Hospital
China Cord Blood Corporation
ChondroCelect
Clal Biotechnology Industries
Cognate BioServices
Cord Blood America
Corestem
Cryo-Cell International
CryoCord
Cryo-Save
www.visiongain.com

17. Contents
CXR Biosciences
CyThera
Cytomedix
Cytori Therapeutics
Denali Ventures
Dendreon
Duke University
Elbit Imaging
Eli Lilly
EpiStem
ES Cell International
European Medicines Agency (EMA)
FCB-Pharmicell
FCB-Twelve
Food and Drug Administration (US FDA)
Forticell Bioscience
Gamida Cell
Garnet BioTherapeutics
General BioTechnology
Geron
GlaxoSmithKline
Global Stem
GMP Unlimited
Greenpeace
Hadassah Medical Organization
Harvard Stem Cell Institute
Histostem
HomeoTherapy
Human Fertilisation and Embryology Authority (HFEA)
Human Stem Cell Institute
www.visiongain.com

18. Contents
ImmunoCellular Therapeutics
Immunovative Therapies
InSCeption Biosciences
Institute of Biomedical Research (Japan)
IntelliCell Biosciences
International Stemcell Services
iPierian
iPS Academia Japan
Israel Healthcare Venture
Israel Stem Cell Society
Ixion Biotechnology
Johnson & Johnson
Lentigen
Lifebank Cryogenics
LifebankUSA
MaRS Innovation
Maxcyte
MedCell Bioscience
Medical Research Council (UK)
Medipost
Medistem Laboratories
Merck & Co.
Merck Millipore
Mesoblast
MetaCyte Business Lab
Miltenyi Biotec
Ministry of Food and Drug Safety, Korea
National Marrow Donor Program (US)
NeoStem
Neuralstem
www.visiongain.com

19. Contents
NeuroGeneration
NeuroSearch
Northern Therapeutics
Novartis
NovoCell
NsGene
NuVasive
OncoCyte
Opexa Therapeutics
OrbusNeich
OrthoCyte
Orthofix
Osiris Therapeutics
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmicell
Plasticell
Pluristem Therapeutics
Progenitor Cell Therapy
Proneuron Biotechnologies
ReCyte Therapeutics
Regenerative Sciences
Regeneron
Regenetech
ReNeuron
Renovo Neural
RhinoCyte
Roslin Cellab
Rutgers University
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
www.visiongain.com

20. Contents
SanBio
Saneron CCEL Therapeutics
Sangamo BioSciences
Sanofi
Schepens Institute
Seoul National University
S-Evans Biosciences
Sirna Therapeutics
Skye Orthobiologics
South Korea Food and Drug Administration (KFDA)
Spinesmith Partners
Stem Cell Authority
Stem Cell Sciences
Stem Cell Therapeutics
Stemcell Technologies
StemCells
StemCore
StemCyte
Stemedica Cell Technologies
StemEx
StemGen
Stemina Biomarker Discovery
Stempeutics Research
Stemride International
Swissmedic
TCA Cellular Therapy
Teva Pharmaceutical Industries
Theradigm
Theratechnologies
TiGenix
www.visiongain.com

21. Contents
United States District Court for the District of Columbia
United Therapeutics
University College London
University of California, San Diego
University of Heidelberg
University of Kyoto
University of Minnesota
University of Texas Health Science Center
University of Wisconsin Alumni Research Foundation
Vesta Therapeutics
ViaCell
ViaCyte
ViroMed Laboratories
Vitro Biopharma
World Health Organization (WHO)
Yonsei University
www.visiongain.com

22. Stem Cell Technologies: World Market
Outlook 2013-2023
Table 6.2 Other Therapeutic Areas Segment: Revenues ($m), AGR (%), CAGR (%),
2018-2023
2018
2019
2020
2021
2022
2023
Revenues ($m )
992
1158
1436
1720
1953
2026
AGR (%)
18
17
24
20
14
4
CAGR (%, 2018-2023)
15
CAGR (%, 2012-2023)
23
Share of overall
m arket (%)
8
8
9
10
10
10
Source: visiongain 2013
Figure 6.1 Other Therapeutic Areas Segment: Revenues ($m), 2012-2023
2500
Revenues ($m)
2000
1500
1000
500
0
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Year
Source: visiongain 2013
6.2 Other Indications for Stem Cell Treatment
This segment includes all areas of therapeutic stem cell R&D outside the treatment of cancers, the
heart and vasculature, and the CNS and eyes. This leaves a large range of disease targets. Some
are more plausible than others, and only three are addressed by formally-approved stem cell
therapies: various non-cancerous blood disorders treated by HSCT; osteobiologics; and tissue
www.visiongain.com
Page 101

23. Stem Cell Technologies: World Market
Outlook 2013-2023
damage as a complication of Crohn’s disease. However, the potential for stem cells extends into
many other indications.
6.2.1 Curing Orphan Diseases with HSCT
The indications for HSCT outside oncology are broad and varied; for the most part, these are
orphan diseases with small patient populations. Some are listed in Table 6.3.
Table 6.3 Diseases Other than Cancers to be Treated with HSCT, 2013
Amegakaryocytic thrombocytopenia
Red cell aplasia
Angioimmunoblastic lymphadenopathy
Aplastic anaemia
Severe combined immunodeficiency
syndrome - X1
Sickle cell anaemia
Autoimmune cytopenia
Sideroblastic anaemia
Diamond Blackfan anaemia
Sjogren's syndrome
Fanconi's anaemia
Thalassaemia major
Haemophagocytic lymphohistiocytosis
Waldenstrom's macroglobulinaemia
X-linked hyper-immunoglobulin e-M
syndrome
X-linked lymphoproliferative syndrome
Source: visiongain 2013
In rare cases, HSCT can cure these diseases: for example, HSCs from HLA-matched sibling
donors can cure sickle cell disease, and, more problematically, beta-thalassemia.
6.2.2 Genetically-Modified HSCs May Cure HIV, Among Other Diseases
One likely future extension of this principle will be autologous stem cell gene therapy: autologous
HSCs will be modified to correct a genetic condition, then reimplanted. Studies have shown that
Wiskott-Aldrich syndrome (an immunodeficiency disorder) can be cured by autologous HSCT if the
HSCs are first virally modified to express the correct gene. Bluebird Bio has two clinical-stage
programmes of this sort, addressing adrenoleukodystrophy and beta-thalassemia (they are not
covered here since this is primarily a gene therapy platform; however, the distinction is somewhat
subjective).This marks an important area of investigation for stem cell therapeutics. One of the
possible extensions of this principle is a potential ‘host-targeting’ cure for HIV, whereby the CCR5
gene is disrupted in host blood cells, removing the receptor used by the virus to gain access to the
www.visiongain.com
Page 102